Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Rectal Neoplasms 1Paraproteinemias 1Neoplasms 1

Interventions

Bortezomib 5Dexamethasone 4Lenalidomide 3Granulocyte Colony-Stimulating Factor 3fludarabine 2filanesib 2dacetuzumab 2Steroids 2Injections, Subcutaneous 2Filgrastim 2plerixafor 1ofatumumab 1isatuximab 1fludarabine phosphate 1ficlatuzumab 1birtamimab 1Zoledronic Acid 1Whole-Body Irradiation 1Vorinostat 1Tacrolimus 1Rifaximin 1Proteasome Inhibitors 1Plasma Exchange 1Mycophenolic Acid 1KW-2478 1Hsp90 inhibitor KU757 1Erlotinib Hydrochloride 1Denosumab 1Cyclophosphamide 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Paraproteinemias × Rifaximin × Clear all
NCT03820817 2026-05-26

Rifaximin in Patients With Monoclonal Gammopathy

Emory University

Phase 1 Completed
50 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡